Liontrust Investment Partners’s Barinthus Biotherapeutics BRNS Stock Holding History

Liontrust Investment Partners’s Portfolio BRNS Stock Details BRNS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-133,918	Closed	-$276K	–	195
2023 Q2	$276K	Sell	133,918 -321,930	-71%	-$762K	﹤0.01%	203
2023 Q1	$1.02M	Sell	455,848 -144,152	-24%	-$401K	0.02%	177
2022 Q4	$1.43M	Hold	600,000	–	–	0.03%	148
2022 Q3	$1.9M	Hold	600,000	–	–	0.03%	195
2022 Q2	$2.67M	Hold	600,000	–	–	0.04%	186
2022 Q1	$3.12M	Hold	600,000	–	–	0.04%	141
2021 Q4	$6.67M	Hold	600,000	–	–	0.08%	120
2021 Q3	$9.44M	Buy	+600,000	New	+$9.11M	0.13%	87

Other funds holding BRNS

MGIM

M&G Investment Management London, United Kingdom $28.2B AUM 25.87% 1-Year Est. Return

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

HSG Holding Na, Hong Kong $1.2B AUM 23.01% 1-Year Est. Return

DC Funds Mclean, Virginia $1.25M AUM 26.51% 1-Year Est. Return

BCM

BlueCrest Capital Management St Helier, Jersey $3.04B AUM 26.78% 1-Year Est. Return

Baird Financial Group Milwaukee, Wisconsin $72.7B AUM 26.4% 1-Year Est. Return

JHU

Johns Hopkins University Baltimore, Maryland $1.5B AUM 13.39% 1-Year Est. Return

IIM

Ipswich Investment Management Beverly, Massachusetts $474M AUM 35.58% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Liontrust Investment Partners's BRNS Position: Q3 2023 in Review

Liontrust Investment Partners sold out of Barinthus Biotherapeutics (BRNS) in Q3 2023, closing a stake of 133,918 shares — an estimated $276K sold.

Liontrust Investment Partners first reported a position in BRNS in Q3 2021 and held it in 8 quarters. The position peaked at $9.44M in Q3 2021. 16 funds tracked by Wall St. Rank hold BRNS as of Q3 2023.

Liontrust Investment Partners reported no remaining Barinthus Biotherapeutics position as of Q3 2023 after selling out during the quarter.
Liontrust Investment Partners sold 133,918 Barinthus Biotherapeutics shares in Q3 2023, an estimated $276K.
Liontrust Investment Partners first reported a position in Barinthus Biotherapeutics in Q3 2021 and held it in 8 quarters.
Liontrust Investment Partners's Barinthus Biotherapeutics position peaked at $9.44M in Q3 2021.
16 funds tracked by Wall St. Rank held Barinthus Biotherapeutics as of Q3 2023.

Based on Liontrust Investment Partners's 13F filing for Q3 2023, filed 9 Nov 2023.